Literature DB >> 7564474

Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia.

M Koike1, T Ishiyama, S Tomoyasu, N Tsuruoka.   

Abstract

We studied spontaneous cytokine production by peripheral blood mononuclear cells (PBMC) obtained from 14 patients with aplastic anemia (AA) and 28 various myelodysplastic syndromes (MDS). The levels of interleukin-6, interleukin-1 beta, and tumor necrosis factor-alpha in cultured PBMC were measured by ELISA. The average levels of these cytokines were higher in AA or in refractory anemia (RA) than in RA with excess of blasts (RAEB) or in RAEB in transformation (RAEB-T). Marked cytokine overproduction was observed in RA as well as in AA. High cytokine levels were observed in hypocellularity and low blast cell counts in the bone marrow. These results may suggest that the increase of cytokines may be a reactive response in hypocellular bone marrow.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7564474     DOI: 10.1016/0145-2126(95)00044-o

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

1.  An unusual cutaneous manifestation of myelodysplastic syndrome: "pseudo-Koebner phenomenon".

Authors:  R DasGupta; S A Fairham; C Womack; C Burton; M Sivakumaran
Journal:  J Clin Pathol       Date:  1998-11       Impact factor: 3.411

2.  Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes.

Authors:  Asaka Kondo; Taishi Yamashita; Hideto Tamura; Wanhong Zhao; Takashi Tsuji; Masumi Shimizu; Eiji Shinya; Hidemi Takahashi; Koji Tamada; Lieping Chen; Kazuo Dan; Kiyoyuki Ogata
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

Review 3.  Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.

Authors:  Elaine M Sloand; A J Barrett
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

4.  Detection of TNFalpha expression in the bone marrow and determination of TNFalpha production of peripheral blood mononuclear cells in myelodysplastic syndrome.

Authors:  L Molnár; T Berki; A Hussain; P Németh; H Losonczy
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

Review 5.  Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.

Authors:  Roberto Castelli; Riccardo Schiavon; Valentina Rossi; Giorgio Lambertenghi Deliliers
Journal:  Med Oncol       Date:  2018-04-19       Impact factor: 3.064

6.  Interferon-gamma and perforin-positive T cells in acquired aplastic anemia: implication in therapeutic response.

Authors:  Vandana Sharma; Prabin Kumar; Rajiv Kumar; Sushmita Chakraborty; Manju Namdeo; Sudha Sazawal; Uma Kanga; Tulika Seth; Dipendra Kumar Mitra
Journal:  Clin Exp Immunol       Date:  2022-05-12       Impact factor: 4.330

7.  Interferon Gamma and perforin positive T cells in acquired aplastic anemia: implication in therapeutic response.

Authors:  Vandana Sharma; Prabin Kumar; Rajiv Kumar; Sushmita Chakraborty; Manju Namdeo; Sudha Sazawal; Uma Kanga; Tulika Seth; Dipendra Kumar Mitra
Journal:  Clin Exp Immunol       Date:  2021-12-10       Impact factor: 5.732

8.  Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment.

Authors:  Tony Navas; Li Zhou; Myka Estes; Edwin Haghnazari; Aaron N Nguyen; Yongkai Mo; Perry Pahanish; Mani Mohindru; Tim Cao; Linda S Higgins; Leonidas C Platanias; Alan List; Amit Verma; T Bhagat; S Gajavelli; S Kambhampati
Journal:  Leuk Lymphoma       Date:  2008-10

9.  The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes.

Authors:  Astrid Olsnes Kittang; Kristoffer Sand; Annette Katharina Brenner; Kristin Paulsen Rye; Øystein Bruserud
Journal:  Int J Mol Sci       Date:  2016-07-05       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.